Akademik Veri Yönetim Sistemi
Eastern Journal of Medicine, cilt.29, sa.3, ss.276-287, 2024 (Scopus)
This study aimed whether S100A4 would be useful in predicting Erectile Dysfunction (ED) and ED severity. This prospective study included 88 male volunteers aged 18-80 years. The control group consisted of 44 healthy patients and the diabetic group consisted of 44 patients with type-2 diabetes (T2DM). Age, body mass index, smoking status, hypertension status, International Index of Erectile Function 1-5 scores of all the volunteers were evaluated, and also glucose, HbA1c, cholesterol, testosterone, prolactin and S100A4 levels were measured in the serum samples. The relationships between S100A4 and erectile functions were investigated with appropriate statistical analyzes. The mean age of the T2DM group was 51.98 ±10.91 years, while the control group’s mean age was 53.77 ±12.46 years and there was no significant difference between them (p=0.31). Glucose, HbA1c, mean ED severity and S100A4 levels in the T2DM group were higher than in the control group, while testosterone level was lower than in the control (p≤0.05). In addition, it was found that S100A4 levels increased due to the increase in ED severity in both groups (p<0.001). In addition to ED severity, smoking and hypertension were seen as the factors that most affected S100A4. The results indicated that S100A4 may be a useful biomarker in determining ED and ED severity.